Myovant Sciences

Biotech · Acquired

Relugolix, a GnRH receptor antagonist small-molecule therapeutic for prostate cancer and uterine fibroids

myovant.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1675Deep Creek Pharma, LLC——
1676Cubist Pharmaceuticals——
1677Orphi Therapeutics Inc——
1678Myovant Sciences——
1679ROKE BIOTECHNOLOGIES LLC——
1680MANDALMED, INC.——
1681PSQUARE SCIENTIFIC, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.